Safety and efficacy of apixaban versus other oral anticoagulants (dabigatran, rivaroxaban or warfarin) in elderly patients with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease

Trial Profile

Safety and efficacy of apixaban versus other oral anticoagulants (dabigatran, rivaroxaban or warfarin) in elderly patients with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2017 New trial record
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top